Aroa Biosurgery Limited (ARX.AX)

AUD 0.7

(2.96%)

Market Cap (In AUD)

239.7 Million

Revenue (In AUD)

63.35 Million

Net Income (In AUD)

-9.74 Million

Avg. Volume

692.74 Thousand

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.44-0.87
PE
-
EPS
-
Beta Value
0.62
ISIN
NZARXE0001S1
CUSIP
Q05263100
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Dr. Brian Ward B.V.Sc, MBA(dist)
Employee Count
-
Website
https://aroabio.com
Ipo Date
2020-07-24
Details
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.